Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.

Basic Information

ID: ALA3112442

Journal: Bioorg Med Chem Lett

Title: Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.

Authors: McDonnell ME, Bian H, Wrobel J, Smith GR, Liang S, Ma H, Reitz AB.

Abstract: We designed a series of anilino-indoylmaleimides based on structural elements from literature JAK3 inhibitors 3 and 4, and our lead 5. These new compounds were tested as inhibitors of JAKs 1, 2 and 3 and TYK2 for therapeutic intervention in rheumatoid arthritis (RA). Our requirements, based on current scientific rationale for optimum efficacy against RA with reduced side effects, was for potent, mixed JAK1 and 3 inhibition, and selectivity over JAK2. Our efforts yielded a potent JAK3 inhibitor 11d and its eutomer 11e. These compounds were highly selective for inhibition of JAK3 over JAK2 and TYK. The compounds displayed only modest JAK1 inhibition.

CiteXplore: 24461299

DOI: 10.1016/j.bmcl.2014.01.001

Patent ID: ┄